Ranking Profile - Galapagos NV

Introduction

Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines for the treatment of inflammatory and fibrotic diseases. It offers Filgotinib medication targeting rheumatoid arthritis (RA). The company is investigating GLPG3667 compound against autoimmune indications, GLPG2737, a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor to treat autosomal dominant polycystic kidney disease,GLPG1690, an oral autotaxin inhibitor targeting idiopathic pulmonary fibrosis (IPF)and GLPG1972 drug to treat osteoarthritis. Galapagos is also evaluating Filgotinib against Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, cutaneous lupus and uveitis. It has operation in the Netherlands, France, Germany, Italy, Spain, Switzerland, the United States and the United Kingdom. Galapagos is headquartered in Mechelen, Belgium.